— Know what they know.
Not Investment Advice

PCRX

Pacira BioSciences, Inc.
1W: -4.9% 1M: -4.6% 3M: -16.7% YTD: -9.6% 1Y: -8.9% 3Y: -43.8% 5Y: -69.5%
$22.11
-0.46 (-2.04%)
After Hours: $21.08 (-1.03, -4.68%)
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $951.2M · Alpha Radar Buy · Power 63
Smart Money Score
Bullish 75
Insider+$0.8M
Congress
ETF Holdings
Key Statistics
Market Cap$951.2M
52W Range18.8-27.64
Volume1,853,506
Avg Volume913,142
Beta0.23
Dividend
Analyst Ratings
16 Buy 16 Hold 4 Sell
Consensus Buy
Company Info
CEOFrank D. Lee
Employees788
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2011-02-03
Websitepacira.com
5401 West Kennedy Boulevard
Tampa, FL 33609
US
813 553 6680
About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Recent Insider Trades

NameTypeSharesPriceDate
SLONIN JONATHAN S-Sale 3,261 $22.82 2026-03-17
Froimson Mark S-Sale 500 $21.81 2026-03-17
Cross Shawn A-Award 49,091 2026-02-11
WILLIAMS KRISTEN A-Award 54,546 2026-02-11
Teehan Brendan A-Award 51,714 2026-02-11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms